HBAR is trading at $0.091054, down 1.69% over 24 hours, while its seven-day decline is 11.52%. This points to clear near-term weakness, although the 30-day change remains positive at 14.82%, showing that the latest losses have not erased the full monthly advance.

Price is below every supplied hourly moving average: the 8-hour measure is $0.0917, the 13- and 21-hour measures are about $0.0927–$0.0928, and the 55- and 144-hour measures are $0.0950 and $0.0993. The gaps grow at longer averages, indicating that price is also well below these reference levels, rather than merely slipping under the shortest one.

The 1-hour RSI is 44 and the seven-day RSI is 41, both below the neutral 50 mark and consistent with weaker momentum. Neither reading, however, signals an extreme condition on its own, so the RSI data supports caution rather than establishing that a rebound is imminent or that selling is exhausted.

The return periods give a mixed picture: HBAR is down 1.93% over 14 days and 11.52% over seven days, but up 14.82% over 30 days. The longer-period gain is a meaningful counterpoint to the bearish short-term readings, yet the recent weekly loss and price position beneath all listed averages suggest that near-term momentum currently carries more weight.

At $0.091054, HBAR is about 34% of the way up from its 24-hour low of $0.088177 to its high of $0.096567. That places it in the lower portion of the day’s range, reinforcing the weak daily performance without establishing a durable floor or a specific support level.

Reported 24-hour volume is 176,446,022, with volume equal to 4.41% of market capitalization. Without comparative volume data, that ratio does not independently confirm or contradict the price move, so it should not outweigh the more direct price and momentum signals.

The overall rating is Sell, reflecting the negative daily and weekly returns, RSI readings below 50, and price trading beneath all supplied moving averages. The positive 30-day return argues against treating the broader period as uniformly bearish, but it does not presently offset the concentration of weaker short-term evidence.